‘Covifenz’ shot uses plant material that resembles virus particles to create immunity

  • The Covifenz plant-based vaccine has been approved for use in people age 18 to 64 by Canadian regulators 
  • It is the first plant based COVID-19 vaccine, and this is the first approval it has earned anywhere in the world
  • Covifenz showed 71% effectiveness as preventing infection from the virus before Omicron arrived late last year 
  • Canadian officials expressed excitement that the homegrown vaccine was a breakthrough for the nation’s biotechnology industry
  • Clinical trials for the jab did not include the Omicron variant, which managed to evade protection provided by other shots 

Covifenz, developed as a joint-venture between Canada‘s Medicago and the UK’s GlaxoSmithKline, uses plant material to mimic the virus’s spike protein once injected into a person’s body.

The vaccine is a two-dose jab that is ‘refrigerator stable’, meaning it does not requires the hyper-cold storage that the Moderna and Pfizer shots do for transport.

Phase 3 trials for the shot included 24,000 adults in six countries. Not enough data for the over 65 age group was gathered for regulators to make a decision.

https://www.dailymail.co.uk/health/article-10549045/Canadian-health-officials-greenlight-PLANT-based-COVID-19-vaccine.html?

AND

Health Canada authorizes Medicago COVID-19 vaccine for adults 18 to 64 years of age

The vaccine is authorized for use in adults 18 to 64 years of age, based on the data that was reviewed by Health Canada. There was limited enrolment of participants older than 65 years of age in the clinical trials because a large proportion of older individuals were already vaccinated. Medicago is currently gathering data in older individuals to support regulatory authorization for this age group.

In keeping with the Department’s commitment to openness and transparency, Health Canada is publishing multiple documents related to its decision, including a high-level summary of the evidence it reviewed to support the authorization of the vaccine. More detailed information will be available in the coming weeks, including a detailed scientific summary and the full clinical trial results that support the use of this vaccine.

https://www.canada.ca/en/health-canada/news/2022/02/health-canada-authorizes-medicago-covid-19-vaccine-for-adults-18-to-64-years-of-age.html

AND

Covifenz (virus-like particles (VLP) of SARS-CoV-2 spike protein)

Resources

Click on a resource to visit a page with more information. You may be taken away from this page to a different Government of Canada website.

https://covid-vaccine.canada.ca/covifenz/product-details